Description of Business Description of Business Evolus, Inc., (Evolus or the Company) is a performance beauty company focused on delivering products in the self-pay aesthetic market. The Company received the approval of its first product Jeuveau  (prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration (the FDA) in February 2019. The product was approved by Health Canada in August 2018 and the European Commission (EC) in September 2019. Jeuveau  is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. The Company commercially launched Jeuveau  in the United States in May 2019 and in Canada through a distribution partner in October 2019. The Company is headquartered in Newport Beach, California. Liquidity and Financial Condition The accompanying unaudited condensed financial statements have been prepared on a basis that assumes that the Company will continue as a going concern, and do not include any adjustments that may result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Companys assets and the satisfaction of the Companys liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Since inception , the Company has incurred recurring net operating losses. T he Company has recorded net losses of $19,735 for the three months ended March 31, 2020 . Additionally, the Company used cash of $27,947 in operations during the three months ended March 31, 2020 . Management expects operating losses and negative cash flows to continue for at least the next 12 months. As of March 31, 2020 , the Company had $34,652 in cash and cash equivalents plus $64,987 in short-term investments and an accumulated deficit of $232,794 . The Companys ability to execute on its business strategy, meet its future liquidity requirements, and achieve profitable operations, is dependent on a number of factors, including its ability to gain and expand market acceptance of its product and achieve a level of revenues adequate to support its cost structure, its ability maintain regulatory approval of its product, its ability to maintain compliance with debt covenants and avoid an event of default under its credit facility, the outcome of its ongoing litigation, and its ability to operate its business and sell products without infringing third party intellectual property rights. The Company believes that its current capital resources, which consist of cash, cash equivalents and short-term investments, are sufficient to fund operations through at least the next twelve months from the date the accompanying financial statements are issued based on the expected cash burn rate. The Company may be required to raise additional capital to fund future operations through the incurrence of additional debt allowed under existing debt arrangements , the entry into licensing or collaboration agreements with partners, sale of its equity securities, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its controllable and variable expenditures and current rate of spending through reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals. The recent COVID-19 outbreak that was first detected in Wuhan, China, in December 2019, has caused economic and social disruption on an unprecedented scale. The COVID-19 outbreak has negatively impacted and disrupted the global economy and financial markets which could interfere with the Companys ability to access financing when and on terms that the Company desires. Although there is uncertainty related to the anticipated impact of the recent COVID-19 outbreak on the Companys future results, the Company believes that its business strategy, its current cash reserves and the recent steps it has taken to reduce operating expenses, such as reducing headcount, temporarily reducing executive salaries and Board of Directors fees, reducing the size of the Board and delaying the European launch of Jeuveau  , position the Company to manage its business through this crisis. See Note 10. Subsequent Events for additional details on the Companys response to the COVID-19 outbreak.